New Delhi: CORONA Remedies Limited, one of the fastest-growing Indian pharmaceutical companies, has been recognized by the World Records India for its groundbreaking “ABHA Study” (Alerting Bharat Through Hypertension Awareness). This initiative aimed to create mass awareness about blood pressure monitoring and hypertension management while achieving a remarkable milestone.
Over 11 days, CORONA Remedies organized free hypertension screenings at 227 locations across India. The campaign saw the participation of 2,036 doctors and facilitated BP screenings for a record-breaking 68,331 patients, culminating in a new world record.
Key insights from the screenings highlight the urgency of hypertension management in India:
- 45.25% of participants were in Stage I or Stage II hypertension, while 15.75% had elevated BP, emphasizing the prevalence of uncontrolled hypertension and increasing disease burden.
- Only 29.65% of individuals had normal BP levels, while 1 in 3 hypertensive patients screened were newly diagnosed, showcasing the critical role of early detection.
- Higher Risk in Males: 48.07% of male participants and 41.15% of females were found to be in hypertension stages, with males showing a significantly higher prevalence of Stage II hypertension.
Additionally, 1 in 10 individuals with high blood pressure exhibited elevated pulse rates, predominantly in adults and middle-aged groups, with females showing a higher pulse rate than males.
Nirav Mehta, CEO of CORONA Remedies Ltd., remarked: “The ABHA Study is a testament to CORONA Remedies’ commitment to improving public health and raising awareness about hypertension. This world record is not just an achievement for our team but a stepping stone toward a healthier Bharat. Early detection and management of hypertension are critical in reducing the disease burden, and we remain dedicated to driving impactful initiatives in this space.”
The study’s success not only underscores the importance of regular BP monitoring but also highlights the need for robust awareness campaigns to tackle the growing hypertension crisis in India. CORONA Remedies aims to continue its efforts in public health through such initiatives, ensuring accessible and effective healthcare solutions for every Indian.
About CORONA Remedies Limited
CORONA Remedies Limited., named after the radiant glow around the sun during an eclipse symbolizing hope, growth, and prosperity, was founded in 2004 and is headquartered in Ahmedabad, India. The company has quickly become one of the Top 30 pharmaceutical firms in the country, specializing in women’s health, cardiovascular care, neuropathy and pain management, respiratory, urology, bone health, and nutritional supplements. Its manufacturing facilities in Ahmedabad and Solan meets the highest global regulatory standards, including WHO-GMP, EU-GMP supporting a broad distribution network across India, Africa, and Southeast Asia.
With over 4,500 employees, CORONA Remedies is committed to ethical, transparent, and innovative practices. The company delivers high-quality, evidence-based products, aiming to make healthcare more accessible and improve patient outcomes in the markets it serves.
For more information, visit https://www.coronaremedies.com/.
Stay updated with the company’s latest developments on LinkedIn (CORONA Remedies Pvt Ltd) and Instagram (coronaremedies).
